<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485146</url>
  </required_header>
  <id_info>
    <org_study_id>ETC-1002-004</org_study_id>
    <nct_id>NCT01485146</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects</brief_title>
  <official_title>A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ETC-1002 at Doses Above 120 mg/Day in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Esperion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Esperion Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1, double-blind (sponsor open), placebo controlled study will assess the safety,
      tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 in healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measuring subject safety by collecting and evaluating vital signs, adverse events, and laboratory measures.</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measuring the level of ETC-1002 and its metabolite ESP15228 in the blood.</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Safety Evaluation of Escalating Doses</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Healthy Subjects in Phase I Unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Healthy Subjects in Phase I Unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Healthy Subjects in Phase I Unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 Healthy Subjects in Phase I Unit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETC-1002</intervention_name>
    <description>escalating doses</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Healthy male and female subjects of non-child bearing potential as determined by
             medical history, physical exam and vial sign measurements

          -  Body Mass Index of 18-32 kg/m2 inclusive with body weight &gt;50 kg

        Major Exclusion Criteria:

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;1.2 x Upper Limit
             of Normal(ULN), serum creatinine &gt;ULN, Hemoglobin &lt;12.0 g/dL

          -  Clinically significant disease that requires a physician's care and/or would interfere
             with study evaluations

          -  History of drug or alcohol abuse, consumption of alcohol within 48 hours prior to
             randomization, or a positive test for alcohol or drugs with a high potential for abuse
             prior to randomization

          -  Use of any prescription or nonprescription drugs, vitamins, or dietary supplements
             within 14 days prior to randomization

          -  Other exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jasper Clinic, Inc.</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>December 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2011</study_first_posted>
  <last_update_submitted>April 12, 2012</last_update_submitted>
  <last_update_submitted_qc>April 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

